Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 80,955 matching trials from the live ClinicalTrials.gov search.
Conditions
Wiskott-Aldrich Syndrome
Interventions
Patient Interview guide, Caregiver interview guide, Sociodemographic questionnaire, Pediatric quality of life (PedsQL) questionnaire, Clinical questionnaire
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 30 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Collegeville, Pennsylvania
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PEG-interferon alfa-2b, temozolomide
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Ischemia
Interventions
Control Group, Single-Dose Heliox Group, Muscle Biopsy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more
Conditions
Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia
Interventions
rituximab
Drug
Lead sponsor
National Pediatric Neuroinflammation Organization, Inc.
Other
Eligibility
6 Months to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Springfield, Illinois
Conditions
Bipolar Depression, Treatment Resistant Bipolar Depression
Interventions
Ketamine, Functional magnetic resonance imaging (fMRI)
Drug · Other
Lead sponsor
Drew Cumming
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • Ohio City, Ohio
Conditions
Acute Myocardial Infarction, Acute Coronary Syndrome
Interventions
high-sensitivity cardiac troponin testing
Diagnostic Test
Lead sponsor
Fred Apple
Other
Eligibility
21 Years and older
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Advanced/Metastatic Malignant Solid Tumors
Interventions
HLX43, HLX10
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Completed Phase 2 Interventional Results available

Phase II 5-Azacytidine Plus VPA Plus ATRA

NCT00326170
Conditions
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Interventions
5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Liver Cancer
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Spinal Fusion
Interventions
Dexmedetomidine
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Withdrawn No phase listed Observational

Verily Watch Cardio (AF and ECG) Study

NCT06041373
Conditions
Atrial Fibrillation
Interventions
Verily Watch Cardio, iRhythm Zio monitor, Schiller CARDIOVIT FT-1
Device
Lead sponsor
Verily Life Sciences LLC
Industry
Eligibility
22 Years and older
Timeline
2023 – 2024
U.S. locations
3
States / cities
Lakewood, Colorado • Southfield, Michigan • Winston-Salem, North Carolina
Completed No phase listed Observational

CCU Wireless Vital Signs Monitoring

NCT04142073
Conditions
CCU Inpatients
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
0 Months to 18 Years
Enrollment
30 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Myelodysplastic Syndromes
Interventions
bortezomib
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, New York
Conditions
Breast Cancer
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
La Jolla, California
Conditions
Chronic Bronchitis
Interventions
Guafenesin tablets
Drug
Lead sponsor
American Health Research
Other
Eligibility
40 Years to 90 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Charlotte, North Carolina • Rock Hill, South Carolina
Completed Not applicable Interventional

BEATS 2: Music Therapy in Sickle Cell

NCT03233269
Conditions
Sickle Cell Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Terminated Phase 4 Interventional Accepts healthy volunteers

Ibuprofen Versus Ketorolac for Pain Relief During Hysterosalpingogram

NCT05190341
Conditions
Infertility, Female
Interventions
Ibuprofen 800 mg oral, Ketorolac 30mg oral
Drug
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions
Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Sorafenib Tosylate, Recombinant Interferon Alfa-2b, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas